Home > Protocol Summaries: Compounds > alosetron Protocol Summaries: alosetron GSKStudy ID Phase Title Status S3B20032 phase 2 A four-week, open, multicenter study to assess the safety and efficacy of 1 mg once daily (QD) of GR68755 in female subjects with severe diarrhea-predominant irritable bowel syndrome (IBS) who have frequent bowel urgency Completed S3B30040 phase 3 A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects with Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy Completed S3B30048 phase 3 A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy Completed S3B40042 Phase 4 A randomize, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects Completed
